Cardiol Therapeutics
CRDL
41 hedge funds and large institutions have $9.85M invested in Cardiol Therapeutics in 2024 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 9 closing their positions.
782% more call options, than puts
Call options by funds: $194K | Put options by funds: $22K
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
0% more funds holding
Funds holding: 41 → 41 (0)
0.7% less ownership
Funds ownership: 7.81% → 7.12% (-0.7%)
9% less capital invested
Capital invested by funds: $10.8M → $9.85M (-$981K)
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIA
Foundations Investment Advisors
Phoenix,
Arizona
|
+$236K |
| 2 |
TC
Tejara Capital
London,
United Kingdom
|
+$102K |
| 3 |
Morgan Stanley
New York
|
+$75.5K |
| 4 |
WANY
Wealthspire Advisors (New York)
New York
|
+$62.9K |
| 5 |
Two Sigma Investments
New York
|
+$51.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$614K |
| 2 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
-$267K |
| 3 |
LNWTC
Laird Norton Wetherby Trust Company
Seattle,
Washington
|
-$202K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$114K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$84.7K |
CRDL Hedge Fund Activity: Q3 2024 in Review
41 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Cardiol Therapeutics (CRDL) for Q3 2024, worth a combined $9.85M — down 9.1% from $10.8M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CRDL positions and 9 closed out — a net gain of 1 holder — while 6 added to existing stakes and 10 trimmed.
The largest buyer was Foundations Investment Advisors, adding an estimated $236K. The largest seller was AdvisorShares Investments, cutting an estimated $614K.
- 41 institutional investors held Cardiol Therapeutics (CRDL) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $9.85M of Cardiol Therapeutics stock for Q3 2024, down 9.1% quarter-over-quarter.
- 10 funds opened new Cardiol Therapeutics positions in Q3 2024 and 9 closed out, a net change of +1 holder.
- The largest Cardiol Therapeutics buyer in Q3 2024 was Foundations Investment Advisors, an estimated $236K added.
- The largest Cardiol Therapeutics seller in Q3 2024 was AdvisorShares Investments, an estimated $614K sold.
Based on aggregated 13F filings for Q3 2024.